NurExone Biologic
Haifa
About NurExone Biologic
NurExone Biologic is developing a biological exosome based technology drug platform to treat damage in the Central Nerve System.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: otcqb:NRXBF
- Website: nurexone.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Clinical Trials
Social Profiles
Canonical: https://fsome.com/organization/nurexone-biologic-98958 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.